Abstract
A cost-effectiveness evaluation system has been introduced in April 2019 to adjust the prices of new health technologies in Japan. At the same time, the specialist development program for health economics evaluation at Keio University has been launched for fourth year. Following the 1st report in FY2021 on this journal from the required class of this program, Special Lecture on Health Economic Evaluation, we report on two drugs of H1 categories which the cost-effectiveness analysis results had already been published. In FY2022, the students who have learned about basic knowledge of health economics mainly participated, and workshop for Mock pre-consultation meeting was held to discuss cost effectiveness analytical framework, which divided into pharmaceutical industries and authorities. In the mock meeting, both parties discussed the analytical framework from their perspectives, and after the mock meeting both parties discussed, and then agreed on the analytical framework. Finally, we discussed and considered the differences between the agreed framework and the analytical framework implemented by the official analysis, and raised issues such as the difficulty of selecting comparative technologies and whether it is possible to evaluate based on a single standard. In addition, we discussed common issues and critical point of the entire system after the class. So we report both deliverables regarding summary of these issues and discussions from student’s perspective.
